283 related articles for article (PubMed ID: 34236111)
1. Peripheral blood lymphocyte subtypes in dogs with different stages of myxomatous mitral valve disease.
Druzhaeva N; Nemec Svete A; Ihan A; Pohar K; Domanjko Petrič A
J Vet Intern Med; 2021 Sep; 35(5):2112-2122. PubMed ID: 34236111
[TBL] [Abstract][Full Text] [Related]
2. Effects of Coenzyme Q
Druzhaeva N; Nemec Svete A; Tavčar-Kalcher G; Babič J; Ihan A; Pohar K; Krapež U; Domanjko Petrič A
Antioxidants (Basel); 2022 Jul; 11(8):. PubMed ID: 35892628
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and their correlation with lipoproteins in dogs with myxomatous mitral valve disease.
Khaki Z; Nooshirvani P; Shirani D; Masoudifard M
BMC Vet Res; 2022 Dec; 18(1):448. PubMed ID: 36564735
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of urinary neutrophil gelatinase-associated lipocalin to detect renal tubular damage in dogs with stable myxomatous mitral valve disease.
Troia R; Sabetti MC; Crosara S; Quintavalla C; Romito G; Mazzoldi C; Fidanzio F; Cescatti M; Bertazzolo W; Giunti M; Dondi F
J Vet Intern Med; 2022 Nov; 36(6):2053-2062. PubMed ID: 36196592
[TBL] [Abstract][Full Text] [Related]
5. Symmetric dimethylarginine in dogs with myxomatous mitral valve disease at various stages of disease severity.
Valente C; Guglielmini C; Domenech O; Contiero B; Zini E; Poser H
PLoS One; 2020; 15(9):e0238440. PubMed ID: 32870923
[TBL] [Abstract][Full Text] [Related]
6. Iron parameters analysis in dogs with myxomatous mitral valve disease.
Kumiega E; A Kobak K; Noszczyk-Nowak A; Kasztura M
BMC Vet Res; 2024 May; 20(1):210. PubMed ID: 38762716
[TBL] [Abstract][Full Text] [Related]
7. The classical and alternative circulating renin-angiotensin system in normal dogs and dogs with stage B1 and B2 myxomatous mitral valve disease.
Hammond HH; Ames MK; Domenig O; Scansen BA; Yang NT; Wilson MD; Sunshine E; Brunk K; Masters A
J Vet Intern Med; 2023; 37(3):875-886. PubMed ID: 36951394
[TBL] [Abstract][Full Text] [Related]
8. Predictors of reoccurrence of congestive signs within 180 days after successful treatment of the first episode of congestive heart failure in dogs with myxomatous mitral valve disease.
Franchini A; Abbott JA; Tyrrell W; Rosenthal S; Lahmers S; Menciotti G; Crosara S; Häggström J; Borgarelli M
J Vet Cardiol; 2021 Apr; 34():112-119. PubMed ID: 33706221
[TBL] [Abstract][Full Text] [Related]
9. Increased serum C-reactive protein concentrations in dogs with congestive heart failure due to myxomatous mitral valve disease.
Reimann MJ; Ljungvall I; Hillström A; Møller JE; Hagman R; Falk T; Höglund K; Häggström J; Olsen LH
Vet J; 2016 Mar; 209():113-8. PubMed ID: 26831162
[TBL] [Abstract][Full Text] [Related]
10. The prevalence of pulmonary hypertension in Cavalier King Charles spaniels compared with other breeds with myxomatous mitral valve disease.
Sudunagunta S; Green D; Christley R; Dukes-McEwan J
J Vet Cardiol; 2019 Jun; 23():21-31. PubMed ID: 31174726
[TBL] [Abstract][Full Text] [Related]
11. Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs.
Nakamura K; Kawamoto S; Osuga T; Morita T; Sasaki N; Morishita K; Ohta H; Takiguchi M
J Vet Intern Med; 2017 Mar; 31(2):316-325. PubMed ID: 28145607
[TBL] [Abstract][Full Text] [Related]
12. Anatomic regurgitant orifice area obtained using 3D-echocardiography as an indicator of severity of mitral regurgitation in dogs with myxomatous mitral valve disease.
Müller S; Menciotti G; Borgarelli M
J Vet Cardiol; 2017 Oct; 19(5):433-440. PubMed ID: 28964709
[TBL] [Abstract][Full Text] [Related]
13. Severity of myxomatous mitral valve disease in dogs may be predicted using neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratio.
Ku D; Chae Y; Kim C; Koo Y; Lee D; Yun T; Chang D; Kang BT; Yang MP; Kim H
Am J Vet Res; 2023 Jun; 84(6):. PubMed ID: 37024099
[TBL] [Abstract][Full Text] [Related]
14. Use of vertebral left atrial size for staging of dogs with myxomatous valve disease.
Mikawa S; Nagakawa M; Ogi H; Akabane R; Koyama Y; Sakatani A; Ogawa M; Miyakawa H; Shigemoto J; Tokuriki T; Toda N; Miyagawa Y; Takemura N
J Vet Cardiol; 2020 Aug; 30():92-99. PubMed ID: 32707334
[TBL] [Abstract][Full Text] [Related]
15. Serial measurements of cardiac troponin I in heart failure secondary to canine mitral valve disease.
Chan IP; Wu SY; Chang CC; Chen WY
Vet Rec; 2019 Sep; 185(11):343. PubMed ID: 31439824
[TBL] [Abstract][Full Text] [Related]
16. Expression Profiling of Circulating MicroRNAs in Canine Myxomatous Mitral Valve Disease.
Li Q; Freeman LM; Rush JE; Laflamme DP
Int J Mol Sci; 2015 Jun; 16(6):14098-108. PubMed ID: 26101868
[TBL] [Abstract][Full Text] [Related]
17. Effect of sampling time on urinary electrolytes following oral furosemide administration in dogs with myxomatous mitral valve disease.
Sabetti MC; Fidanzio F; Troìa R; Perissinotto L; Romito G; Mazzoldi C; Quintavalla C; Crosara S; Dondi F
J Vet Cardiol; 2022 Jun; 41():57-69. PubMed ID: 35245876
[TBL] [Abstract][Full Text] [Related]
18. A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease.
Newhard DK; Jung S; Winter RL; Duran SH
J Vet Intern Med; 2018 Sep; 32(5):1555-1563. PubMed ID: 30084228
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of serum ionized magnesium concentration in dogs with myxomatous mitral valve disease.
Kim OK; Kim K; Park S; Yang H; Kim H; Ro WB; Lee CM
J Vet Intern Med; 2024; 38(1):41-50. PubMed ID: 38064361
[TBL] [Abstract][Full Text] [Related]
20. Urine 5-hydroxyindoleacetic acid in Cavalier King Charles spaniels with preclinical myxomatous mitral valve disease.
Christiansen LB; Cremer SE; Helander A; Madsen T; Reimann MJ; Møller JE; Höglund K; Ljungvall I; Häggström J; Olsen LH
Vet J; 2019 Aug; 250():36-43. PubMed ID: 31383418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
